Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, finds that the pharmaceutical market for mild cognitive impairment will emerge within five to ten years, fueled by the anticipated launch of the first disease-modifying drugs for the treatment of Alzheimer's disease, rising diagnosis rates, and a projected 20% increase in drug- treatment rates.

The drug market for mild cognitive impairment, which totaled $77 million in 2003, is currently in its infancy, according to the new Pharmacor study entitled Mild Cognitive Impairment. Current diagnostic rates are extremely low in the United States, Western Europe, and Japan, due to the heterogeneous patient population and the uncertainty of which patients will progress to dementia and would thereby benefit most from treatment.

"Drug-treatment rates are hobbled by the unimpressive efficacy of current drugs, which address only the symptoms of dementia, and the fact that mild cognitive impairment is not recognized as an approvable indication by regulatory agencies," said Andrea S. Witt, Ph.D., analyst at Decision Resources. "The market will develop thanks to Neurochem's Alzhemed and Myriad Genetics' Flurizan, both of which we expect will launch between 2008 and 2013 and will be used off-label for the treatment of mild cognitive impairment."

The study also finds that, by 2013, disease-modifying therapies will represent more than 77% of the mild cognitive impairment drug market.

About Pharmacor from Decision Resources

Pharmacor is a unique family of studies that assesses a host of market- impacting factors and analyzes the commercial outlook for drugs in research and development.

About Decision Resources

Decision Resources, Inc., (http://www.decisionresources.com/) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Elizabeth Marshall    Decision Resources, Inc.    781-296-2563    emarshall@dresources.com 

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-2563,
emarshall@dresources.com

Increase in Polypharmacy for the Treatment of Pulmonary Arterial Hypertension Will Grow the Market

View Now